PLDT Inc. Sponsored ADR (PHI)

SG&A Expenses

₱69.66B

TTM · Period ending: · PHP

PHI logo

PHI SG&A Expenses

Latest reported₱69.66B PHP
PHI TTM SG&A Expenses · PHP (₱0.00 → ₱69.66B)
High-resolution chart · PNG

PHI sg&a expenses history

Trailing twelve months (TTM) · PHP. Each value covers four complete reported quarters.

PLDT Inc. Sponsored ADR SG&A Expenses — Trailing twelve months (TTM) (PHP)
Period endingSG&A Expenses (PHP)
69,661,389,000
70,360,389,000
70,503,389,000
58,015,000,000
57,964,000,000
59,312,000,000
68,632,000,000
71,578,000,000
71,644,000,000
70,757,000,000
63,930,000,000
61,825,000,000
62,905,000,000
64,970,000,000
68,661,000,000
68,482,000,000
67,882,000,000
66,003,000,000
62,168,000,000
65,687,000,000
63,092,000,000
59,661,000,000
59,218,000,000
55,899,000,000
57,922,000,000
57,757,000,000
56,945,000,000
59,694,000,000
58,488,000,000
60,259,000,000
62,252,000,000
60,559,000,000
55,453,000,000
51,122,000,000
50,895,000,000
49,916,000,000
49,231,000,000
47,725,000,000
46,993,000,000
47,887,000,000
47,848,000,000
49,513,000,000
49,109,000,000
47,665,000,000
48,043,000,000
46,871,000,000
47,157,000,000
49,363,000,000
48,844,000,000
47,514,000,000
47,591,000,000
34,144,000,000
38,311,000,000
47,213,000,000
50,895,000,000
56,263,000,000
52,486,000,000
42,258,000,000
36,482,000,000
36,367,000,000
36,325,000,000
38,202,000,000
41,262,000,000
49,774,000,000
49,276,000,000
49,492,000,000
49,181,000,000
47,262,405,550
49,995,531,150
48,821,778,590
48,168,449,670
41,047,602,080
38,848,062,090
39,175,979,230
38,975,461,590
45,923,765,880
44,814,241,320
42,974,837,060
40,300,416,290
37,847,452,690
36,199,211,560
34,299,431,770
33,821,082,580
38,342,791,790
36,570,421,950
35,618,040,980
35,206,467,140
30,528,837,664
32,036,410,403
32,180,806,013
30,403,986,143
31,172,273,678
30,277,636,949
31,264,616,021
31,927,497,879
32,730,153,458
30,086,073,089
27,822,765,685
26,752,260,337
19,178,226,110
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.